Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsPeptide CJC-1295 (no DAC / mod GRF 1-29)
PeptideInjectablePeptideGHRH analogueSecretagogue

CJC-1295 (no DAC / mod GRF 1-29)

Also known as Mod GRF 1-29 · Modified GRF(1-29) · CJC-1295 no DAC · CJC-1295 DAC-free

CJC-1295 without DAC, commonly sold as modified GRF(1-29), is a short-acting growth-hormone-releasing hormone analogue. Four amino-acid substitutions on the GHRH(1-29) fragment resist enzymatic degradation, giving a brief but potent GH pulse. It is frequently paired with a GHRP (e.g. ipamorelin) for synergistic release. Human evidence is limited; use is largely anecdotal.

01 Overview

Modified GRF(1-29) stimulates the pituitary to release growth hormone in a pulse that preserves physiological feedback, unlike direct GH administration. Its short half-life means it is dosed once or several times daily, often at night to mimic natural nocturnal GH pulses.

It is typically combined with a ghrelin-mimetic GHRP because the two act on different receptors and amplify each other's GH release. Controlled human data at physique doses is scarce; the parent GHRH(1-29) has been studied clinically, but the specific analogue as used non-medically has not. Effects and side effects here reflect mechanism and anecdote.

02 Mechanism

Analogue of GHRH(1-29) that binds the pituitary GHRH receptor to stimulate synthesis and pulsatile release of endogenous growth hormone; amino-acid substitutions resist DPP-4 degradation for a slightly prolonged action versus native GHRH.

03 Dosing

TierDoseRouteNotes
Anecdotal (non-medical)100 mcgSubQ~100 mcg per injection, often 1-3x/day; commonly combined with a GHRP.

04 Effects

EffectMagnitudeEvidence
Raised GH and IGF-1Stimulates a pulsatile GH release and downstream IGF-1 rise; magnitude in non-medical use is not well quantified in humans.Preclinical
Improved sleepNight-time dosing reportedly deepens slow-wave sleep, consistent with GHRH physiology.Anecdotal
Fat loss and recoveryReported modest fat loss and faster recovery; not established in controlled trials at these doses.Anecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Injection-site reactionsRedness, itching or swelling at the injection site.MildCommonAnecdotal
Transient flushing/head rushWarmth, facial flushing or light-headedness minutes after dosing.MildCommon shortly after injectionAnecdotal
Water retention / carpal-tunnel-like symptomsMild fluid retention or wrist tingling, as with any GH elevation.MildUncommon at typical dosesAnecdotal

07 References

Modified GRF(1-29) / GHRH analogue pharmacologyPubMed
GHRH and its analogues in GH secretionPubMed search

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.